Transcriptomics

Dataset Information

0

Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemia


ABSTRACT: T-prolymphocytic leukemia (T-PLL) is a rare, aggressive T-cell malignancy with poor outcomes and an urgent need for new therapeutic approaches. Integrating genomic data and new transcriptomic profiling, we identified recurrent JAK/STAT mutations as a hallmark in T-PLL in an unprecedented cohort of 335 T-PLL cases, predominantly involving JAK3 and STAT5B. In line, transcriptomic and immunoblot analyses revealed constitutive JAK/STAT activation in virtually all samples. Building on these findings, we explored the therapeutic potential of dual STAT3/STAT5 non-PROTAC degraders in T-PLL treatment, with JPX-1244 as our lead substance. JPX-1244 efficiently and selectively induced cell death in primary T-PLL samples, including those resistant to conventional therapies, by blocking STAT3/STAT5 phosphorylation and inducing their degradation. The extent of STAT3/STAT5 degradation directly correlated with cytotoxicity. RNA-sequencing confirmed the downregulation of STAT5 target genes. While JAK/STAT mutations did not predict treatment responses, elevated TOX, PAK6, and SPINT1 expression was associated with drug sensitivity. In a subsequent combination screening, cladribine, venetoclax, and azacytidine emerged as most effective combination partners even in low-responding T-PLL samples, synergistically reducing STAT5 phosphorylation. These findings highlight dual STAT3/STAT5 inhibition, particularly in combination with hypomethylating agents, as a promising therapeutic approach in T-PLL, warranting further preclinical and clinical investigation.

ORGANISM(S): Homo sapiens

PROVIDER: GSE286270 | GEO | 2025/06/16

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2017-05-22 | GSE87687 | GEO
2024-12-10 | GSE263984 | GEO
2022-11-02 | GSE163361 | GEO
2025-05-14 | GSE289764 | GEO
2022-11-04 | MSV000090647 | MassIVE
2019-05-16 | GSE131300 | GEO
2024-06-16 | PXD043558 | Pride
2024-04-15 | GSE219155 | GEO
2023-01-25 | PXD037895 | Pride
2018-07-23 | GSE100844 | GEO